Amneal Pharmaceuticals (NASDAQ:AMRX) Shares Gap Up to $5.40

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) shares gapped up prior to trading on Wednesday . The stock had previously closed at $5.40, but opened at $5.76. Amneal Pharmaceuticals shares last traded at $5.79, with a volume of 637,860 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AMRX shares. Barclays upped their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Piper Sandler lifted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Finally, The Goldman Sachs Group upped their price target on Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a research note on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Amneal Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $7.31.

Amneal Pharmaceuticals Trading Up 12.8 %

The firm has a fifty day moving average of $5.71 and a 200-day moving average of $5.17. The company has a debt-to-equity ratio of 121.31, a quick ratio of 0.94 and a current ratio of 1.63. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -19.42 and a beta of 1.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings results on Friday, March 1st. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $616.98 million during the quarter, compared to analysts’ expectations of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 126.04% and a negative net margin of 3.51%. As a group, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Gladius Capital Management LP bought a new stake in Amneal Pharmaceuticals in the third quarter valued at about $39,000. Trexquant Investment LP acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $65,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $54,000. TCG Advisory Services LLC bought a new stake in Amneal Pharmaceuticals during the fourth quarter valued at $91,000. Finally, Bellevue Group AG acquired a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth $155,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.